Benzisoxazole derivatives having d4-antagonistic activity
    1.
    发明授权
    Benzisoxazole derivatives having d4-antagonistic activity 有权
    具有d4拮抗活性的苯并异恶唑衍生物

    公开(公告)号:US06335326B1

    公开(公告)日:2002-01-01

    申请号:US09601795

    申请日:2000-10-23

    IPC分类号: A01N4346

    CPC分类号: C07D413/14

    摘要: The present invention relates to a group of novel benzisoxazole derivatives which are potent and selective antagonists of the dopamine D4-receptor. The compounds have general formula (I) wherein (R1)n represents 0, 1, or 2 substituents, which can be the same or different, from the group C1-3-alkyl or alkoxy, halogen, trifluoromethyl, nitro, amino mono- or dialkyl (C1-2)-amino, sulfonyl-(C1-3)alkyl or -alkoxy, sulfonyl trifluoromethyl, sulfonyl amino, and sulfonyl mono- or dialkyl (C1-2)-amino, X is O, S, NH or NCH3, Y represents CH2, or (CH2)2, (R2)m represents 0, 1, or 2 substituents, which can be the same or different, from the group methyl and ethyl, or (R2)m is a methylene bridge or ethylene bridge, A is a group —CH2—(CRH)p— wherein R is hydrogen or methyl and p is 0 or 1, and B represents 2- or 3-indolyl or 2-benzimidazolyl, which groups may be substituted at carbon with 1 or 2 substituents from the group C-1-3-alkyl or alkoxy, halogen, trifluoromethyl, nitro, amino, mono- or dialkyl (C1-2)amino, sulfonyl-(C1-3)alkyl or -alkoxy, sulfonyl trifluoromethyl, sulfonyl amino, and sulfonyl mono- or dialkyl (C1-2)-amino.

    摘要翻译: 本发明涉及一组新的苯并异恶唑衍生物,其是多巴胺D4受体的有效和选择性拮抗剂。 化合物具有通式(I),其中(R1)n表示0,1或2个可以相同或不同的取代基,可以是C1-3 - 烷基或烷氧基,卤素,三氟甲基,硝基, 或二烷基(C1-2) - 氨基,磺酰基 - (C1-3)烷基或 - 烷氧基,磺酰基三氟甲基,磺酰基氨基和磺酰基单 - 或二烷基(C1-2) - 氨基,X是O,S,NH或 NCH 3,Y表示CH 2或(CH 2)2,(R 2)m表示0,1或2个与甲基和乙基基团相同或不同的取代基,或(R2)m是亚甲基桥或 乙基桥,A是-CH 2 - (CRH)p - 基团,其中R是氢或甲基,p是0或1,B表示2-或3-吲哚基或2-苯并咪唑基,该基团可以在碳上被取代, 1或2个C 1-3 - 烷基或烷氧基,卤素,三氟甲基,硝基,氨基,一或二烷基(C 1-2)氨基,磺酰基 - (C 1-3)烷基或 - 烷氧基,磺酰基三氟甲基 ,磺酰基氨基和磺酰基单或二烷基(C 1-2) - 氨基。

    2-aminoquinoline derivatives having d4-agonistic activity
    2.
    发明授权
    2-aminoquinoline derivatives having d4-agonistic activity 有权
    具有d4-激动活性的2-氨基喹啉衍生物

    公开(公告)号:US06281216B1

    公开(公告)日:2001-08-28

    申请号:US09601765

    申请日:2000-10-23

    IPC分类号: A61K31496

    摘要: The present invention relates to a group of novel 2-aminoquinoline derivatives which are potent and selective agonists of the dopamine D4-receptor. The compounds have general formula (I) wherein (R1)n represents 1 or 2 substituents, which can be the same or different, from the group C1-3-alkyl or alkoxy, halogen, trifluoromethyl, nitro, amino, and mono- or dialkyl (C1-2)amino, or two groups R1 at adjacent carbon atoms together with the benzene ring may form the benzdioxane group or benzofuran group, X represents nitrogen or carbon, and the dotted line may represent a double bond, (R2)p represents 0, 1 or 2 substituents, which can be the same or different, from the group methyl and ethyl, or (R2)p is a methylene bridge or ethylene bridge, R3 is hydrogen or methyl, and (R)m represents 0, 1, or 2 substituents, which can be the same or different and can be located at all available positions of the quinolyl group, from the group C1-3-alkyl or alkoxy, halogen, trifluoromethyl, nitro, amino, and mono- or dialkyl (C1-2)amino, on the understanding that R1 cannot represent o-OCH3 when X is nitrogen, (R2)p and R3 are hydrogen, m is 0 and n is 1

    摘要翻译: 本发明涉及一组新的2-氨基喹啉衍生物,其是多巴胺D4-受体的有效和选择性激动剂。 化合物具有通式(I),其中(R1)n表示1或2个可以相同或不同的取代基,可以是C1-3 - 烷基或烷氧基,卤素,三氟甲基,硝基,氨基和单 - 或 二烷基(C1-2)氨基或相邻碳原子上的两个基团R 1与苯环可以形成苯并二恶烷基或苯并呋喃基,X代表氮或碳,虚线可以表示双键,(R2)p 代表0,1或2个与甲基和乙基基团相同或不同的取代基,或(R2)p是亚甲基桥或乙烯桥,R3是氢或甲基,(R)m表示0, 1或2个取代基,其可以相同或不同,并且可以位于喹啉基的所有可用位置,C 1-3 - 烷基或烷氧基,卤素,三氟甲基,硝基,氨基和单 - 或二烷基 (C1-2)氨基,可以理解,当X是氮时,R1不能表示o-OCH3,(R2)p和R3是氢,m是0,而ni s 1

    Phenylpiperazines
    4.
    发明授权
    Phenylpiperazines 有权
    苯基哌嗪

    公开(公告)号:US07456182B2

    公开(公告)日:2008-11-25

    申请号:US11450323

    申请日:2006-06-12

    摘要: The invention relates to a novel group of phenylpiperazines having interesting pharmacological properties such as a high affinity for the dopamine D2 receptor and/or the serotonin reuptake site, and the ability to treat conditions related to disturbances in the dopaminergic and/or the serotonergic systems such as anxiety disorders, depression, Parkinson's disease, and schizophrenia.The invention relates to a group of novel phenylpiperazine derivatives of the formula (I): wherein: X is a group of formula 1, 2, 3, 4, 5, 6, or 7 as defined in the text, m has the value 2 to 6; n has the value 0-2; R5 and R6 are independently H or alkyl (1-3C); or R5+R6 represent a group —(CH2)—p wherein p has the value 3-5, and R7 is alkyl (1-3C), alkoxy (1-3C), halogen or cyano; or R6+R7 (R7 at position 7 of the indole group) represent a group —(CH2)q wherein q has the value 2-4, and salts thereof.

    摘要翻译: 本发明涉及具有令人感兴趣的药理学性质的新一组苯基哌嗪,例如对多巴胺D 2 O受体和/或5-羟色胺再摄取位点的高亲和力,以及治疗与 多巴胺能和/或血清素能系统如焦虑障碍,抑郁症,帕金森病和精神分裂症。 本发明涉及一组新的式(I)的苯基哌嗪衍生物:其中:X是本文定义的式1,2,3,4,5,6或7的基团,m的值为2 至6; n的值为0-2; R 5和R 6独立地是H或烷基(1-3C); 或R 5 + R 6表示基团 - (CH 2)2 - ,其中p的值为3 -5和R 7是烷基(1-3C),烷氧基(1-3C),卤素或氰基; 或吲哚基的第7位上的R 6(R 7)表示 - (CH 2)2 - 其中q具有2-4,及其盐。

    Phenylpiperazine
    6.
    发明授权
    Phenylpiperazine 失效
    苯基哌嗪

    公开(公告)号:US07605162B2

    公开(公告)日:2009-10-20

    申请号:US12258591

    申请日:2008-10-27

    IPC分类号: A61K31/496 C07D403/12

    摘要: The invention relates to a novel group of phenylpiperazines having interesting pharmacological properties such as a high affinity for the dopamine D2 receptor and/or the serotonin reuptake site, and the ability to treat conditions related to disturbances in the dopaminergic and/or the serotonergic systems such as anxiety disorders, depression, Parkinson's disease, and schizophrenia.The invention relates to a group of novel phenylpiperazine derivatives of the formula (I): wherein: X is a group of formula 1, 2, 3, 4, 5, 6, or 7 as defined in the text, m has the value 2 to 6; n has the value 0-2; R5 and R6 are independently H or alkyl (1-3C); or R5+R6 represent a group —(CH2)—p wherein p has the value 3-5, and R7 is alkyl (1-3C), alkoxy (1-3C), halogen or cyano; or R6+R7 (R7 at position 7 of the indole group) represent a group —(CH2)q wherein q has the value 2-4, and salts thereof.

    摘要翻译: 本发明涉及具有令人感兴趣的药理学性质的新一组苯基哌嗪,例如对多巴胺D2受体和/或5-羟色胺再摄取位点的高亲和力,以及治疗与多巴胺能和/或血清素能系统中的干扰相关的病症的能力,例如 作为焦虑障碍,抑郁症,帕金森病和精神分裂症。 本发明涉及一组新的式(I)的苯基哌嗪衍生物:其中:X是本文定义的式1,2,3,4,5,6或7的基团,m的值为2 至6; n的值为0-2; R5和R6独立地是氢或烷基(1-3C); 或R 5 + R 6表示基团 - (CH 2)p - 其中p具有3-5,R 7是烷基(1-3C),烷氧基(1-3C),卤素或氰基; 或R6 + R7(吲哚基的第7位的R7)表示基团 - (CH 2)q,其中q具有2-4,及其盐。

    New Phenylpiperazine
    8.
    发明申请
    New Phenylpiperazine 失效
    新苯基哌嗪

    公开(公告)号:US20090143406A1

    公开(公告)日:2009-06-04

    申请号:US12258591

    申请日:2008-10-27

    IPC分类号: A61K31/496 C07D403/04

    摘要: The invention relates to a novel group of phenylpiperazines having interesting pharmacological properties such as a high affinity for the dopamine D2 receptor and/or the serotonin reuptake site, and the ability to treat conditions related to disturbances in the dopaminergic and/or the serotonergic systems such as anxiety disorders, depression, Parkinson's disease, and schizophrenia.The invention relates to a group of novel phenylpiperazine derivatives of the formula (I): wherein: X is a group of formula 1, 2, 3, 4, 5, 6, or 7 as defined in the text, m has the value 2 to 6; n has the value 0-2; R5 and R6 are independently H or alkyl (1-3C); or R5+R6 represent a group —(CH2)—p wherein p has the value 3-5, and R7 is alkyl (1-3C), alkoxy (1-3C), halogen or cyano; or R6+R7 (R7 at position 7 of the indole group) represent a group —(CH2)q wherein q has the value 2-4, and salts thereof.

    摘要翻译: 本发明涉及具有令人感兴趣的药理学性质的新一组苯基哌嗪,例如对多巴胺D2受体和/或5-羟色胺再摄取位点的高亲和力,以及治疗与多巴胺能和/或血清素能系统中的干扰相关的病症的能力,例如 作为焦虑障碍,抑郁症,帕金森病和精神分裂症。 本发明涉及一组新的式(I)的苯基哌嗪衍生物:其中:X是本文定义的式1,2,3,4,5,6或7的基团,m的值为2 至6; n的值为0-2; R5和R6独立地是氢或烷基(1-3C); 或R 5 + R 6表示基团 - (CH 2)p - 其中p具有3-5,R 7是烷基(1-3C),烷氧基(1-3C),卤素或氰基; 或R6 + R7(吲哚基的第7位的R7)表示基团 - (CH 2)q,其中q具有2-4,及其盐。